We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DuPont's Q4 Earnings and Sales Top Estimates on Higher Volumes
Read MoreHide Full Article
DuPont de Nemours, Inc. (DD - Free Report) registered a loss from continuing operations of 17 cents per share in the fourth quarter of 2024, compared with a loss of 72 cents per share in the year-ago quarter.
Barring one-time items, earnings came in at $1.13 per share in the reported quarter, up from 87 cents a year ago. It topped the Zacks Consensus Estimate of 98 cents.
Find the latest earnings estimates and surprises on Zacks Earnings Calendar.
DuPont logged net sales of $3,092 million, marking a 7% year-over-year increase. It also beat the Zacks Consensus Estimate of $3,066.8 million. The upside was due to an 8% increase in volume that more than offset a 1% decline in price. The rise in volume was driven by sustained strong demand in the electronics market, a return of year-over-year growth in medical packaging and biopharma and further growth in water markets.
DuPont de Nemours, Inc. Price, Consensus and EPS Surprise
The company's Electronics & Industrial segment reported net sales of $1,506 million in the quarter, an 11% year-over-year increase. It was higher than the consensus estimate of $1,504.2 million. Organic sales grew 10%, driven by an 11% rise in volume, which was modestly offset by a 1% decrease in price.
The Water & Protection unit recorded net sales of $1,359 million, a 6% rise from the previous year, beating the consensus estimate of $1,348.2 million. The upside was due to an 8% increase in volumes, partly offset by 2% lower prices.
DD’s FY24 Results
Earnings (as reported) from continuing operations for full-year 2024 were $1.77 per share compared with $1.09 per share a year ago. Net sales went up around 3% year over year to $12,386 million.
DD’s Financials
DuPont had cash and cash equivalents of $1,850 million at the end of 2024, down around 23% year over year. Long-term debt was $5,323 million, down 32% year over year.
The company generated operating cash flow from continuing operations of $2.3 billion in 2024.
DuPont’s Outlook
DuPont anticipates full-year 2025 net sales to be in the range of $12,800-$12,900 million. Operating EBITDA for the full year is forecast to be $3,325-$3,375 million while adjusted earnings are projected to be $4.30-$4.40 per share for the year.
For the first quarter of 2025, DD forecasts net sales of around $3,025 million, operating EBITDA of roughly $760 million and adjusted earnings of around 95 cents per share.
DD Stock’s Price Performance
DuPont’s shares have gained 11.3% in a year against the Zacks Chemicals Diversified industry’s 3.4% decline.
Ingevity is scheduled to release fourth-quarter results on Feb. 18. The Zacks Consensus Estimate for NGVT’s fourth-quarter earnings is pegged at 12 cents. NGVT surpassed the Zacks Consensus Estimate in three of the trailing four quarters while missing once. It has a trailing four-quarter earnings surprise of 95.4%, on average.
ICL Group is slated to release fourth-quarter results on Feb. 26. The consensus estimate for ICL’s fourth-quarter earnings is pegged at 6 cents. It surpassed the Zacks Consensus Estimate for earnings in each of the last four quarters at an average of 18.1%.
Nutrien is scheduled to release fourth-quarter results on Feb. 19. The Zacks Consensus Estimate for NTR’s fourth-quarter earnings is pegged at 33 cents. NTR has gained around 4% in the past year.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Bigstock
DuPont's Q4 Earnings and Sales Top Estimates on Higher Volumes
DuPont de Nemours, Inc. (DD - Free Report) registered a loss from continuing operations of 17 cents per share in the fourth quarter of 2024, compared with a loss of 72 cents per share in the year-ago quarter.
Barring one-time items, earnings came in at $1.13 per share in the reported quarter, up from 87 cents a year ago. It topped the Zacks Consensus Estimate of 98 cents.
Find the latest earnings estimates and surprises on Zacks Earnings Calendar.
DuPont logged net sales of $3,092 million, marking a 7% year-over-year increase. It also beat the Zacks Consensus Estimate of $3,066.8 million. The upside was due to an 8% increase in volume that more than offset a 1% decline in price. The rise in volume was driven by sustained strong demand in the electronics market, a return of year-over-year growth in medical packaging and biopharma and further growth in water markets.
DuPont de Nemours, Inc. Price, Consensus and EPS Surprise
DuPont de Nemours, Inc. price-consensus-eps-surprise-chart | DuPont de Nemours, Inc. Quote
DuPont’s Segment Highlights
The company's Electronics & Industrial segment reported net sales of $1,506 million in the quarter, an 11% year-over-year increase. It was higher than the consensus estimate of $1,504.2 million. Organic sales grew 10%, driven by an 11% rise in volume, which was modestly offset by a 1% decrease in price.
The Water & Protection unit recorded net sales of $1,359 million, a 6% rise from the previous year, beating the consensus estimate of $1,348.2 million. The upside was due to an 8% increase in volumes, partly offset by 2% lower prices.
DD’s FY24 Results
Earnings (as reported) from continuing operations for full-year 2024 were $1.77 per share compared with $1.09 per share a year ago. Net sales went up around 3% year over year to $12,386 million.
DD’s Financials
DuPont had cash and cash equivalents of $1,850 million at the end of 2024, down around 23% year over year. Long-term debt was $5,323 million, down 32% year over year.
The company generated operating cash flow from continuing operations of $2.3 billion in 2024.
DuPont’s Outlook
DuPont anticipates full-year 2025 net sales to be in the range of $12,800-$12,900 million. Operating EBITDA for the full year is forecast to be $3,325-$3,375 million while adjusted earnings are projected to be $4.30-$4.40 per share for the year.
For the first quarter of 2025, DD forecasts net sales of around $3,025 million, operating EBITDA of roughly $760 million and adjusted earnings of around 95 cents per share.
DD Stock’s Price Performance
DuPont’s shares have gained 11.3% in a year against the Zacks Chemicals Diversified industry’s 3.4% decline.
DD’s Zacks Rank & Key Picks
DD currently carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the Basic Materials space are Ingevity Corporation (NGVT - Free Report) , ICL Group Ltd (ICL - Free Report) and Nutrien Ltd. (NTR - Free Report) . While NGVT carries a Zacks Rank #1 (Strong Buy), ICL and NTR have a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Ingevity is scheduled to release fourth-quarter results on Feb. 18. The Zacks Consensus Estimate for NGVT’s fourth-quarter earnings is pegged at 12 cents. NGVT surpassed the Zacks Consensus Estimate in three of the trailing four quarters while missing once. It has a trailing four-quarter earnings surprise of 95.4%, on average.
ICL Group is slated to release fourth-quarter results on Feb. 26. The consensus estimate for ICL’s fourth-quarter earnings is pegged at 6 cents. It surpassed the Zacks Consensus Estimate for earnings in each of the last four quarters at an average of 18.1%.
Nutrien is scheduled to release fourth-quarter results on Feb. 19. The Zacks Consensus Estimate for NTR’s fourth-quarter earnings is pegged at 33 cents. NTR has gained around 4% in the past year.